In the DEG profiling of AML-NK patients, about 72% (n = 18/25) of the genes that were reported in AML studies were overexpressed in the DX samples that included several oncogenes (FLT3, MYB, DNMT3B, and MYCN). This evidence concerns the gene FLT3 and acute myeloid leukemia.